Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is...
Transcript of Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is...
![Page 1: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/1.jpg)
Miquel Àngel Seguí Palmer
![Page 2: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/2.jpg)
![Page 3: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/3.jpg)
HER2+ Breast Cancer is characterized by overexpression of HER2 receptors
![Page 4: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/4.jpg)
HER2+ Breast Cancer is characterized by overexpression of HER2 receptors
![Page 5: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/5.jpg)
HER2+ status is associated with more aggressive brest cancer and poorer patients outcomes
![Page 6: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/6.jpg)
HER2HER1/EGFR HER4HER3
Transmembranedomain
Intracellular tyrosine kinase domain
Extracellular ligand-binding domain
The human epidermal growth factor receptors (HER) are a family of structurally-related cell surface proteins
Rowinsky. Oncologist. 2003. Yarden et al. Nature Rev Mol Cell Biol. 2001
![Page 7: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/7.jpg)
Among all possible dimers, the HER2:HER3 pair has the strongest mitogenic signaling
Tzahar et al. Mol Cell Biol. 1996. Lenferink et al. EMBO J. 1998
![Page 8: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/8.jpg)
AKTPDK1
Cell cyclecontrol
Proliferation
ApoptosisSurvival
RAS Sos Grb2 Shc
MEK
Angiogenesis
Raf
PI3K
Cyclin D1
p27
BAD
GSK3ß
NFκBmTOR
MAPK
HER2 HER3
P P PPP
PP
HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation and cell survival
Olayioye et al. EMBO J. 2000. Rowinsky. Oncologist. 2003
![Page 9: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/9.jpg)
![Page 10: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/10.jpg)
![Page 11: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/11.jpg)
Treatment Algorithm (before Cleopatra)
In 1st line Combination of trastuzumab and a taxane
Slamon DJ et al. N Engl J Med. 2001;344:783-92
Efficacy of HER2-targeted therapy in metastatic breast cancer
![Page 12: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/12.jpg)
Treatment Algorithm (before Cleopatra)
In 1st line Combination of trastuzumab and a taxane
Efficacy of HER2-targeted therapy in metastatic breast cancer
Lapatinib or Trastuzumab Plus Taxane (NCIC CTG MA.31)Gelmon KA et al. J Clin Oncol 2015, 32:1574-1583
![Page 13: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/13.jpg)
1st line
2nd line
3rd line
Capecitabina + Lapatinib
QT + Trastuzumab
QT + Trastuzumab
Capecitabina + Lapatinib
Taxane + Trastuzumab
Geyer CE et al. N Engl J Med. 2006;355:2733-43. von Minckwitz G et al. J Clin Oncol. 2009;27:1999-2006
Treatment Algorithm (before Cleopatra and Emilia)
Efficacy of HER2-targeted therapy in metastatic breast cancer
![Page 14: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/14.jpg)
GBG 26/BIG 3-05 phase III study
von Minckwitz et al. Eur J Cancer. 2011;47:2273-81
Post-progression survival according to anti-HER2 treatment or not as part of 3rd line treatment
Efficacy of HER2-targeted therapy in metastatic breast cancer
![Page 15: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/15.jpg)
Efficacy of HER2-targeted therapy in metastatic breast cancer
Dawood et al. J Clin Oncol 2010
![Page 16: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/16.jpg)
Efficacy of HER2-targeted therapy in metastatic breast cancer
Dawood et al. J Clin Oncol 2010
![Page 17: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/17.jpg)
Efficacy of HER2-targeted therapy in metastatic breast cancer
Historical Evolution
![Page 18: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/18.jpg)
Adjuvant Trastuzumab Trials: Disease-Free Survival
Romond et al. Cancer Res. 2012. Piccart-Gebhart et al. Cancer Res. 2012. Slamon et al. N Engl J Med. 2011. Spielmann et al. Breast Cancer Res Treat. 2007. Joensuu et al. J Clin Oncol. 2009
![Page 19: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/19.jpg)
PLANNED JOINT ANALYSIS OF OVERALL SURVIVAL FROM NSABP B-31 AND NCCTG N9831
8-year incidence rate of deaths by cardiac causes: 0.2% (Trastuzumab regimen) and 0.1% (control arm)
Adjuvant Trastuzumab Data
![Page 20: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/20.jpg)
Piccart-Gebhart M et al ASCO 2014
![Page 21: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/21.jpg)
Piccart-Gebhart M et al ESMO 2014
![Page 22: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/22.jpg)
Effect of Trastuzumab on Neo-Adjuvant Therapy for HER2-Positive Disease
Meta-analysis evaluating the pCR rate
Valachis et al., The Breast 2011
![Page 23: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/23.jpg)
Effect of Trastuzumab on Neo-Adjuvant Therapy for HER2-Positive Disease
Buzdar A, et al. JCO 2005; 23:3676. Gianni et al., Lancet 2010
NOAH: tpCRMD Anderson: pCR
![Page 24: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/24.jpg)
Lapatinib or trastuzumab added to preoperative chemotherapy for breast cancer
Forest plot of pCR: trastuzumab versus lapatinib
Valachis et al. Breast Cancer Res Treat. 2012
![Page 25: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/25.jpg)
Potential Molecular Mechanisms of Trastuzumab Resistance
![Page 26: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/26.jpg)
The landmark development of trastuzumab, a humanized monoclonal antibody targeting HER2, and other anti-HER2 agents such as lapatinib, a reversible HER2 tyrosine kinase inhibitor, have changed the course of HER2-positive disease; however, a subset of patients will still relapse.
Given this clinical reality, new anti-HER2 agents with different mechanisms of action have been developed
![Page 27: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/27.jpg)
Novel anti-HER2 therapies or agents that interfere with the HER2 pathway and function
![Page 28: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/28.jpg)
Dual HER2 Blockade
Lapatinib + trastuzumab
![Page 29: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/29.jpg)
Lapatinib + trastuzumab vs. Lapatinib in HER2+ MBC progressing on or after trastuzumab
Dual HER2 Blockade
Overall Survival Progression-Free Survival
![Page 30: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/30.jpg)
Dual HER2 Blockade
NeoALTTO: Study Design
![Page 31: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/31.jpg)
NeoALTTO Study
Dual HER2 Blockade
Baselga et al. Lancet. 2012
![Page 32: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/32.jpg)
EFS shown for the ITT population OS shown for the ITT population
Dual HER2 Blockade
![Page 33: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/33.jpg)
![Page 34: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/34.jpg)
Dual HER2 Blockade
Pertuzumab prevents HER2:HER3 dimer formation by inhibiting access to the HER2 dimerization domain
![Page 35: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/35.jpg)
Dual HER2 Blockade
NEOSPHERE: Study Design
![Page 36: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/36.jpg)
Dual HER2 Blockade
NeoSphere pCR rates: ITT Population Summary
Gianni L, et al. Lancet Oncol 2012; 13:25–32
![Page 37: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/37.jpg)
Dual HER2 Blockade
NeoSphere pCR rates: ITT Population Summary
Gianni L, et al. Lancet Oncol 2012; 13:25–32
![Page 38: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/38.jpg)
NeoSphere DFS (all arms of therapy, ITT population)
Dual HER2 Blockade
Gianni L et al. ASCO 2015
![Page 39: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/39.jpg)
Neoadjuvant Treatment of Breast Cancer
Perjeta is indicated for use in combination with trastuzumab andchemotherapy for the neoadjuvant treatment of adult patients withHER2-positive, locally advanced, inflammatory, or early stage breastcancer at high risk of recurrence
![Page 40: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/40.jpg)
CLEOPATRA: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer
Dual HER2 Blockade
Baselga et al. NEJM 2012
![Page 41: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/41.jpg)
Swain SM et al. N Engl J Med 2015;372:724-34
Dual HER2 Blockade
Median progression-free survival: 18.7 months Median overall survival: 56.5 months
CLEOPATRA
![Page 42: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/42.jpg)
Treatment Algorithm (after Cleopatra)
In 1st line Combination of trastuzumab, pertuzumab and a taxane
Swain SM et al. N Engl J Med 2015;372:724-34
Dual HER2 Blockade
Median progression-free survival: 18.7 months Median overall survival: 56.5 months
![Page 43: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/43.jpg)
Adjuvant Trial: APHINITY
Dual HER2 Blockade
![Page 44: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/44.jpg)
Trastuzumab emtansine (T-DM1)
The mAb, trastuzumab, is conjugated by a thioether linker to the highly potent antimicrotubule agent DM1
![Page 45: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/45.jpg)
Trastuzumab emtansine (T-DM1)
![Page 46: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/46.jpg)
Trastuzumab emtansine (T-DM1)
![Page 47: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/47.jpg)
Trastuzumab emtansine (T-DM1)
![Page 48: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/48.jpg)
Trastuzumab emtansine (T-DM1)
![Page 49: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/49.jpg)
EMILIA, a phase III study of TDM1 versus capecitabine and lapatinib
Verma S et al. N Engl J Med. 2012;367(19):1783-91
![Page 50: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/50.jpg)
Progression-free Survivalas Assessed by an Independent Review Committee
EMILIA, a phase III study of TDM1 versus capecitabine and lapatinib
Verma S et al. N Engl J Med. 2012;367(19):1783-91
![Page 51: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/51.jpg)
EMILIA, a phase III study of TDM1 versus capecitabine and lapatinib
Verma S et al. N Engl J Med. 2012;367(19):1783-91
Second Interim Analysis of Overall Survival
![Page 52: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/52.jpg)
TH3RESA, a Phase III study of TDM1 versus TPC
Krop IE et al. Lancet Oncol. 2014;15(7):689-99
![Page 53: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/53.jpg)
TH3RESA, a Phase III study of TDM1 versus TPC
Krop IE et al. Lancet Oncol. 2014;15(7):689-99
Progression-free survival by investigator assessment First interim overall survival analysis
![Page 54: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/54.jpg)
MARIANNE: Trial Design
T-DM1
![Page 55: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/55.jpg)
Progression-Free Survival by IRF
ORR: HT 67.9%, T-DM1 59.7%, T-DM1+P 64.2%DURATION OF RESPONSE: HT 12.5m, T-DM1 20.7m, T-DM1-P 21.2m
Ellis, ASCO 2015
MARIANNE: Progression Free Survival
T-DM1
![Page 56: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/56.jpg)
1st line
2nd line
3rd line Capecitabina + Lapatinib
QT + Trastuzumab
QT + Trastuzumab
Capecitabina + Lapatinib
Docetaxel + Trastuzumab + Pertuzumab
TDM1
4th line
Lapatinib + Trastuzumab
TDM1 Early relapse
TDM1
TDM1Lapatinib + Trastuzumab
Treatment Algorithm(after CLEOPATRA, EMILIA & TH3RESA)
Efficacy of HER2-targeted therapy in metastatic breast cancer
![Page 57: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/57.jpg)
Number of lines of chemotherapy by line and subtype
Median duration of chemotherapy according to line and subtype
Use and Duration of Chemotherapy in Patients With Metastatic Breast Cancer According to Tumor Subtype and Line of Therapy
Seah DSE et al. J Natl Compr Canc Netw 2014;12:71–80
![Page 58: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/58.jpg)
• Overexpression of the HER2 predicts a poor prognosis in breast cancer.
• HER2 signaling is initiated by receptor homodimerization or heterodimerization with ligand-bound HER1, HER3, and HER4.
• The introduction of HER2-targeted therapies, has significantly improved outcomes in HER2+ breast cancer compared with previously available therapies
• Despite the improvement in overall survival with the addition of HER2-targeted agents to chemotherapy, many patients do not benefit from these agents because of inherent resistance. In addition, many patients who achieve an initial response eventually acquire drug resistance.
Conclusions (1)
![Page 59: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/59.jpg)
• New anti-HER2 drugs have the potential to change clinical practice.
• The combination of pertuzumab plus trastuzumab plus a taxane, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival and overall survival.
• T-DM1 is clearly distinct from trastuzumab; it is a cytotoxic agent, albeit one with an exceptional tolerability profile and has demonstrated clinical superiority in trastuzumab-pretreated and trastuzumab-and lapatinib-pretreated patients.
• T-DM1 is now been recognized as the preferred treatment option in second and third line for patients with advanced HER2-positive breast cancer
Conclusions (2)
![Page 60: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/60.jpg)
Research into HER2-positive metastaticbreast cancer has advanced, but that’sno reason to stop……
![Page 61: Miquel Àngel Seguí Palmer - academia.cat · Miquel Àngel Seguí Palmer. HER2+ Breast Cancer is characterized by overexpression of HER2 receptors. HER2+ Breast Cancer is characterized](https://reader031.fdocuments.net/reader031/viewer/2022011923/60560a4d441a50543a03b4c7/html5/thumbnails/61.jpg)